Login to Your Account



Alder shares pop on midstage migraine data with CGRP-inhibiting candidate

By Michael Fitzhugh
Staff Writer

Monday, March 28, 2016

Positive top-line efficacy data for migraine prevention drug ALD403 pushed Alder Biopharmaceuticals Inc. shares 50 percent higher by Monday market close.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription